Relatlimab, a LAG-3 inhibitor, has been employed in the treatment of advanced melanoma, with ongoing clinical trials evaluating various LAG-3 inhibitors, underscoring the potential of LAG-3 as a promising therapeutic target in melanoma treatment. The gene discussed is LAG3; the disease is melanoma.